4-chloro-6-(chloromethyl)pyrimidin-2-amine | 92311-35-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-chloro-6-(chloromethyl)pyrimidin-2-amine
• 英文别名: 2-amino-4-chloro-6-chloromethylpyrimidine
• CAS: 92311-35-8
• 化学式: C₅H₅Cl₂N₃
• 分子量: 178.021
• InChiKey: MIRFGLZGZZWAQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-chloro-6-(chloromethyl)pyrimidin-2-amine 在 caesium fluoride 作用下， 以 N-甲基乙酰胺 为溶剂， 生成 4-氟-6-(氟甲基)-2-嘧啶胺
  参考文献：
  名称：

  Process for 4,6-di-substituted 2-aminopyrimidines

  摘要：

  新化合物可用作生物活性化合物的中间体，其化学式为I ##STR1## 其中Y是具有公式--CH.sub.2 X的基团，其中X是F、Cl或Br，或Y是具有公式##STR2##的基团，其中R.sup.2是F、Cl或Br，而R.sup.3是H、F、Cl、Br或具有公式--CR.sup.4 R.sup.5 R.sup.6的基团，其中R.sup.4、R.sup.5和R.sup.6独立地是F、Cl或Br；A是H、OH、SH、F、Cl、Br或--OR.sup.7或--SR.sup.7的基团，其中R.sup.7是C.sub.1-C.sub.4直链或支链烷基、C.sub.2-4直链或支链烷基，其上有1至3个F、Cl或Br原子取代，或A是--NR.sup.8 R.sup.9的基团，其中R.sup.8和R.sup.9独立地是H、C.sub.1-C.sub.4直链或支链烷基或C.sub.3-C.sub.4烯基，或R.sup.8和R.sup.9共同形成C.sub.3-C.sub.7聚亚甲基链，该链可以被氧原子打断；以及化合物I与酸的盐；但是，当Y为CH.sub.2 F时，A的定义如上所述，但不包括OH、Cl或OCH.sub.3。

  公开号：

  US04723006A1
• 作为产物：
  描述：

  2-Amino-6-(hydroxymethyl)pyrimidin-4(1H)-one 在 三氯氧磷 作用下， 以96%的产率得到4-chloro-6-(chloromethyl)pyrimidin-2-amine
  参考文献：
  名称：

  The effect of pKa on pyrimidine/pyridine-derived histamine H4 ligands

  摘要：

  During the course of our efforts toward the discovery of human histamine H-4 antagonists from a series of 2-aminiopyrimidines, it was noted that a 6-trifluoromethyl group dramatically reduced affinity of the series toward the histamine H-4 receptor. This observation was further investigated by synthesizing a series of ligands that varied in pK(a) of the pyrimidine derived H-4 ligands by over five orders of magnitude and the effect on histamine H-4 affinity. This trend was then extended to the discovery of C-linked piperidinyl-2- amino pyridines as histamine H-4 receptor antagonists. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.10.013

文献信息

• [EN] SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS<br/>[FR] COMPOSÉS SPIROCYCLIQUES EN TANT QU'INHIBITEURS DE LA TRYPTOPHANE HYDROXYLASE
  申请人：KAROS PHARMACEUTICALS INC

  公开号：WO2015035113A1

  公开（公告）日：2015-03-12

  The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

  本发明涉及一种螺环化合物，它们是色氨酸羟化酶（TPH）的抑制剂，特别是异构体1（TPH1），可用于治疗与外周血清素相关的疾病或紊乱，例如胃肠道、心血管、肺部、炎症、代谢和低骨密度疾病，以及血清素综合征和癌症。
• SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS
  申请人：Karos Pharmaceuticals, Inc.

  公开号：US20150080393A1

  公开（公告）日：2015-03-19

  The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

  本发明涉及螺环化合物，它们是色氨酸羟化酶（TPH）的抑制剂，特别是isoform 1（TPH1），可用于治疗与外周血清素相关的疾病或疾病，例如胃肠道、心血管、肺部、炎症、代谢和低骨量疾病，以及血清素综合症和癌症。
• Spirocyclic compounds as tryptophan hydroxylase inhibitors
  申请人：Karos Pharmaceuticals, Inc.

  公开号：US09199994B2

  公开（公告）日：2015-12-01

  The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

  本发明涉及螺环化合物，其是色氨酸羟化酶（TPH）的抑制剂，特别是isoform 1（TPH1），可用于治疗与外周血清素相关的疾病或疾病，例如胃肠道，心血管，肺部，炎症，代谢和低骨量疾病，以及血清素综合征和癌症。
• 2-Aminopyrimidines, their production and use
  申请人：CIBA-GEIGY AG

  公开号：EP0111440A1

  公开（公告）日：1984-06-20

  New compounds useful as intermediates for biologically-active compounds have the formula I wherein Y is a group having the formula -CH2X in which X is F, Cl, or Br, or Y is a group having the formula in which R2 is F, Cl or Br and R3 is H. F, Cl, Br or a group having the formula -CR4R5R6, in which R4, R5 and R6, independently, are F, Cl or Br; A is H, OH, SH, F, Cl, Br or a group -OR7 or -SR7 in which R7 is C1-C4 straight- or branched chain alkyl, C2-4 straight- or branched chain alkyl substituted with 1 to 3 F, Cl or Br atoms, or A is a group -NR8R9 in which R8 and R9, independently, are H, C1-C4 straight- or branched chain alkyl or C3-C4 alkenyl, or R8 and R9 together may form a C3-C7 polymethylene chain, which is optionally interrupted by an oxygen atom; as well as salts of compounds of formula I with acids; provided that: when Y is CH2F, then A is as hereinbefore defined other than OH, Cl or OCH3.

  可用作生物活性化合物中间体的新化合物具有式 I 其中 Y 是具有式 -CH2X 的基团，式中 X 是 F、Cl 或 Br，或 Y 是具有式 -CH2X 的基团，式中 R2 是 F、Cl 或 Br，R3 是 H。 其中 R2 是 F、Cl 或 Br，R3 是 H、F、Cl、Br 或具有式 -CR4R5R6 的基团，其中 R4、R5 和 R6 分别是 F、Cl 或 Br； A 是 H、OH、SH、F、Cl、Br 或基团 -OR7 或 -SR7，其中 R7 是 C1-C4 直链或支链烷基、被 1 至 3 个 F、Cl 或 Br 原子取代的 C2-4 直链或支链烷基，或 A 是基团 -NR8R9 ，其中 R8 和 R9 独立地是 H、C1-C4 直链或支链烷基或 C3-C4 烯基，或 R8 和 R9 可一起形成 C3-C7 聚亚甲基链，该链可选择被氧原子打断；以及式 I 化合物与酸的盐类；条件是 当 Y 为 CH2F 时，则 A 如前定义，但不是 OH、Cl 或 OCH3。
• US4723006A
  申请人：——

  公开号：US4723006A

  公开（公告）日：1988-02-02